Navigation Links
European Medicines Agency (EMA) Waives Requirement to Test StemEx(R) in Paediatric Patients 17 Years of Age and Under
Date:1/18/2010

JERUSALEM, Israel, January 18 /PRNewswire/ --

- The International Study of StemEx, an Experimental Treatment for Leukemia, Lymphoma and MDS, is now Enrolling at Clinical Sites in Italy, Hungary, Spain, Israel and the U.S.

The Gamida Cell-Teva Joint Venture (JV) announced today that the Paediatric Committee (PDCO) of the EMA has granted product specific waivers for StemEx for all subsets of the paediatric population (birth to 17 years of age) in all conditions. The PDCO emphasized that the granting of the waivers should not prevent the JV from considering developing StemEx for children with conditions where there is a need. StemEx is being developed by a joint venture equally owned and operated by Gamida Cell and Teva Pharmaceuticals ( TEVA).

In order to register a new medicinal product in the European Union, a company generally needs to clinically prove efficacy and safety in paediatric patients in addition to adults. Moreover, a company has to submit to the PDCO a Paediatric Investigational Plan (PIP) for the four existing paediatric age subsets which cover from birth to 17 years of age. The JV submitted a PIP for the age group 12 -17 together with product specific waiver requests for the three age groups between birth to 11 years of age.

As the added value of StemEx lies primarily in the treatment of larger children and adult patients, the PDCO waiver is congruent with the JV's strategy to develop StemEx initially for adolescents and adults.

Ms. Michal Austin, director of regulatory affairs said, "It is well known that the limited number of stem cells in cord blood inhibits the therapeutic use of cord blood transplantation in adolescents and adults. Gamida Cell's technology takes this small population of cord blood stem cells and cultures it with limited differentiation, to a size that has the potential to offer a therapeutic treatment to larger children and adults. Thus, the goal of the JV is for StemEx to significantly widen the scope of a base treatment, already common practice in children. As such, we believe, and the Agency has agreed, that our first priority in developing StemEx will be to offer the treatment to those patients with the most unmet clinical need, meaning adolescents and adults. This means, we are still on track for a 2011 market launch."

Gamida Cell is currently enrolling for the study of StemEx as an investigational treatment for adolescents (larger children) and adults with leukemia at leading cord blood transplant clinical sites in Italy, Hungary, Spain, Israel and the U.S. For more information about the study: http://www.stemexstudy.com.

About Gamida Cell

Gamida Cell Ltd. is a world leader in stem cell expansion technologies and therapeutic products. The company is developing a pipeline of products in stem cell transplantation and in tissue regeneration to effectively treat debilitating and often fatal illnesses such as cancer, hematological, autoimmune and ischemic diseases. Gamida Cell's therapeutic candidates contain populations of adult stem cells, selected from non-controversial sources such as umbilical cord blood and bone marrow, which are expanded in culture. Gamida Cell was successful in translating these proprietary expansion technologies into robust and validated manufacturing processes under GMP. Gamida Cell's flagship product, StemEx, is now being studied as a therapy for patients with blood cancers in an international pivotal trial at leading transplant centers in the U.S., Europe and Israel. StemEx has orphan drug designation in the U.S. and in Europe. Gamida Cell's current shareholders include: Elbit Imaging, Biomedical Investment, Israel Healthcare Venture, Teva Pharmaceutical Industries, Amgen, Denali Ventures and Auriga Ventures. For more information, please visit: http://www.gamida-cell.com.

    Press contact:

    Marjie Hadad
    Media Liaison/IR
    Gamida Cell
    marjie@gamida-cell.com
    +972-54-536-5220

SOURCE Gamida Cell Ltd.


'/>"/>
SOURCE Gamida Cell Ltd.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. CV Therapeutics Announces Eight Abstracts Accepted for Presentation at the European Society of Cardiology Congress 2007
2. Boston Scientific Announces Schedule for European Society of Cardiology Congress 2007
3. European Experts Recommend Pregnant and Nursing Women Take More DHA - Every Day
4. Genasense(R) Data in Melanoma to be Presented in Opening Session at First Worldwide Melanoma Center Meeting of the European Association of Dermato-Oncology
5. Terumo Heart to Announce Results of European Clinical Trial of DuraHeart(TM) LVAS at European Association of Cardiothoracic Surgeons Meeting in September
6. Threshold Pharmaceuticals Announces Two Presentations on Glufosfamide at the 2007 European Cancer Conference (ECCO)
7. Study Results for Aclidinium Bromide, a Novel Anticholinergic, Presented at European Respiratory Society Annual Congress
8. Life Recovery Systems Receives European CE Mark Approval for Its ThermoSuit(R) System
9. Lilly Files for European Approval of ALIMTA(R) (pemetrexed for injection) for First-Line Treatment of Non-Small Cell Lung Cancer
10. European Unions CHMP Issues Positive Opinion on PEGINTRON(TM) Combination Therapy for Retreating Hepatitis C Patients Who Failed Previous Therapy
11. Positive Xeloda(R) Five-Year Overall Survival Study Data in the Adjuvant Treatment of Colon Cancer Presented at Leading European Cancer Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/21/2017)... EDMONTON, Alberta , July 21, 2017 /PRNewswire/ ... University of Alberta in Edmonton, Canada ... partner journal, Schizophrenia 1 , demonstrating that AI ... schizophrenia with 74% accuracy. This retrospective analysis also ... symptoms in schizophrenia patients with significant correlation, based ...
(Date:7/21/2017)... 21, 2017  Endo International plc (NASDAQ: ... review of its manufacturing network, the Company will be ... in Huntsville, Alabama . The closure ... the next 12 to 18 months. The ... volumes of commoditized products and these restructuring actions are ...
(Date:7/20/2017)... PAUL, Minn. , July 20, 2017  Prime Therapeutics ... Jonathan Gavras , M.D., following today,s Institute for Clinical ... report on the effectiveness and value of abuse-deterrent ... manager on the policy roundtable at the meeting. ... is not a material cost benefit to the use of ...
Breaking Medicine Technology:
(Date:7/25/2017)... ... , ... “Now Hiring!” is a popular phrase at Home Delivery Incontinent ... sales for over 30 consecutive years and now plans to hire more than 100 ... excitement and growth at HDIS, following the company’s acquisition by Fortune 1000 company Domtar. ...
(Date:7/25/2017)... ... July 25, 2017 , ... ... the launch of their partnership to provide the Pharmacist eCare Plan ... platform in the country with the ability to develop the Pharmacist eCare Plan, ...
(Date:7/25/2017)... Spring Arbor, Mich. (PRWEB) , ... July 25, ... ... director of special education programs at Spring Arbor University recently co-authored and published ... of Self-Determination in Adolescents with Neonatal Brachial Plexus Palsy. Both the article and ...
(Date:7/25/2017)... ... 25, 2017 , ... Facing medical needs with a newborn boy this spring, ... a new benefit for employees that is uncommon in American business: 12 weeks of ... me and other employees as new parents. It keeps our family life more stable. ...
(Date:7/24/2017)... ... 24, 2017 , ... Engineers at the University of Maryland have invented an ... of electrical energy that the body uses. , In ordinary batteries the electrical ... electrons out of the battery is generated by moving positive ions from one end ...
Breaking Medicine News(10 mins):